Literature DB >> 2110550

pp60c-src protein kinase activity in human gastric carcinomas.

N Takekura1, W Yasui, K Yoshida, T Tsujino, H Nakayama, T Kameda, H Yokozaki, Y Nishimura, H Ito, E Tahara.   

Abstract

We examined pp60c-src protein kinase activity in human gastric carcinoma cell lines and gastric carcinoma tissues as well as normal mucosa. pp60c-src kinase activity was detected in all 5 carcinoma cell lines at various levels. Of 16 gastric carcinoma tissues, 8 showed higher pp60c-src kinase activity in tumor tissues than in corresponding normal mucosa. However, the levels of expression of pp60c-src detected by Western blotting were not always consistent with the activities of pp60c-src protein kinase. These findings suggest that the increase in pp60c-src protein kinase activity might be brought about by post-translational changes.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2110550     DOI： 10.1002/ijc.2910450510

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.

Authors:  J Jankowski; G Coghill; D Hopwood; K G Wormsley
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

3.  The expression of c-src gene in the carcinogenesis process of human cardia adenocarcinoma.

Authors:  Xiu-Jie Wang; Shu-Lan Yuan; Lin Xiao; Xu-Hua Wang; Chao-Jun Wang
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

4.  A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.

Authors:  Helen J Mackay; Heather J Au; Elaine McWhirter; Thierry Alcindor; Andrea Jarvi; Katrina MacAlpine; Lisa Wang; John J Wright; Amit M Oza
Journal:  Invest New Drugs       Date:  2011-03-12       Impact factor: 3.850

5.  Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma.

Authors:  Reiko Ito; Hirofumi Nakayama; Kazuhiro Yoshida; Shunji Matsumura; Noriko Oda; Wataru Yasui
Journal:  Virchows Arch       Date:  2004-02-26       Impact factor: 4.064

6.  17β-estradiol inhibits mesenchymal stem cells-induced human AGS gastric cancer cell mobility via suppression of CCL5- Src/Cas/Paxillin signaling pathway.

Authors:  Chao-Hung Kuo; Chung-Jung Liu; Chien-Yu Lu; Huang-Ming Hu; Fu-Chen Kuo; Yu-Sen Liou; Yuan-Chieh Yang; Ming-Chia Hsieh; Oscar K Lee; Deng-Chyang Wu; Sophie S W Wang; Yao-Li Chen
Journal:  Int J Med Sci       Date:  2013-12-10       Impact factor: 3.738

7.  Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis.

Authors:  Adriano Azevedo Mello; Mariana Ferreira Leal; Juan Antonio Rey; Giovanny Rebouças Pinto; Leticia Martins Lamarão; Raquel Carvalho Montenegro; Ana Paula Negreiros Nunes Alves; Paulo Pimentel Assumpção; Barbara do Nascimento Borges; Marília Cardoso Smith; Rommel Rodriguez Burbano
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

8.  Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.

Authors:  Kyoung-Min Choi; Eunji Cho; Geul Bang; Seong-Jae Lee; Boram Kim; Ji-Hee Kim; Seo-Gyu Park; Eun Hee Han; Young-Ho Chung; Jin Young Kim; Eunjung Kim; Jae-Young Kim
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

9.  Suppression of IL-8-Src signalling axis by 17β-estradiol inhibits human mesenchymal stem cells-mediated gastric cancer invasion.

Authors:  Chung-Jung Liu; Fu-Chen Kuo; Chiu-Lin Wang; Chao-Hung Kuo; Sophie S W Wang; Chiao-Yun Chen; Yaw-Bin Huang; Kuang-Hung Cheng; Kazunari K Yokoyama; Chun-Lin Chen; Chien-Yu Lu; Deng-Chyang Wu
Journal:  J Cell Mol Med       Date:  2016-03-06       Impact factor: 5.310
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.